Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study.
Chiricozzi A, Balato A, Conrad C, Conti A, Dapavo P, Ferreira P, Gaiani FM, Leite L, Malagoli P, Mendes-Bastos P, Megna M, Messina F, Nidegger A, Odorici G, Panduri S, Piaserico S, Piscitelli L, Prignano F, Ribero S, Valerio J, Torres T.
Chiricozzi A, et al. Among authors: malagoli p.
J Dermatolog Treat. 2020 Aug;31(5):476-483. doi: 10.1080/09546634.2019.1671577. Epub 2019 Oct 2.
J Dermatolog Treat. 2020.
PMID: 31557063
Free article.
Clinical Trial.